Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, The Netherlands, discusses a five-year analysis of the MURANO study (NCT02005471) which compared fixed-duration venetoclax plus rituximab therapy with bendamustine plus rituximab therapy in patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Five-year follow-up data found sustained progression-free survival (PFS) and overall survival (OS) with venetoclax plus rituximab. Undetectable minimal residual disease (uMRD) at the end of treatment was associated with improved OS in the venetoclax-rituximab cohort. This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.